Randomized Parkinson’s Trial of GDNF Administered via Intermittent Intraputamenal Convection-Enhanced Delivery.
Objective: Assesing the neurorestorative effect of GDNF. Background: GDNF is a potent neurotrophic factor. A previous placebo-controlled trial, however, at 6 months, failed to demonstrate…Communication Calendar for Interdisciplinary Therapy of Parkinson’s Disease
Objective: To develop a communication calendar (CC) to facilitate information exchange about outpatients treated by various therapists in order to optimize interdisciplinary therapy of Parkinson's…Physical activity habits in early Parkinson’s disease and healthy controls
Objective: Investigate the physical activity habits of Parkinson’s disease (PD) and healthy control (HC) participants of the PPMI cohort. Background: Exercise can improve the motor…Identification of a trehalose treatment regimen with potential to be translated into a therapeutic for the treatment of Parkinson’s disease
Objective: To evaluate the preclinical efficacy of trehalose and to identify a dosing regimen that can be used to clinically evaluate trehalose as a disease-modifying therapy…Clinical and Imaging and phenoconversion in the PARS prodromal cohort
Objective: We report clinical and imaging phenoconversion data at 6 years follow-up for the PARS cohort. Background: The PARS cohort consists of 203 hyposmic and…Deep brain stimulation in early stage Parkinson’s disease: Is it disease modifying?
Objective: To examine patterns of motor symptom worsening in the 2 years following deep brain stimulation (DBS) in early stage Parkinson's disease (PD). Background: Although…Evaluation of regional changes in striatal DAT binding in a progressing Parkinson’s disease (PD) cohort: Lessons for imaging biomarker assessment in disease-modifying therapeutic trials
Objective: To evaluate subregion-dependent striatal changes in dopamine transporter (DAT) binding using 123-I Ioflupane SPECT in PD participants in the Parkinson Progression Marker Initiative (PPMI)…Fifteen years of clinical trials in Huntington’s disease: Too many clinical trial failures
Objective: To investigate the trends in Huntington's disease (HD) therapeutic development by analyzing interventional clinical trials publicly registered for the last 15 years. Background: Like…Disease-related variables effect on depression and anxiety level in Parkinson’s patients
Objective: To evaluate correlations of depression and anxiety levels with motor symptoms, non-motor symptoms and pharmacological factors in Parkinson's disease (PD). Background: Depression and anxiety…Human-derived α-synuclein antibody BIIB054 binds pathologic forms of α-synuclein and attenuates transmission of α-synuclein in vitro and in vivo
Objective: To identify and characterize a human antibody against α-synuclein (α-syn) for the clinical development of an immunotherapy for Parkinson's disease (PD). Background: α-syn plays…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.